I'm LongbridgeAI, I can summarize articles.According to the Zhitong Finance APP, Xintian Pharma announced that the company recently received the "Drug Clinical Trial Approval Notice" for Xinlikang capsules issued by the National Medical Products Administration, approving the clinical trial for "treatment of cancer-related fatigue."
According to the Zhitong Finance APP, Xintian Pharma (002873.SZ) announced that the company recently received the "Drug Clinical Trial Approval Notice" for Xinlikang capsules issued by the National Medical Products Administration, approving the clinical trial for "the treatment of cancer-related fatigue."